Governance
Investors
  • About us
    • Profile
    • Management
    • Board
    • Scientific Advisory Board
  • Our Science
    • Strategy
    • Enabling Technologies
    • Product Classes
  • Pipeline
    • Pipeline
    • NidlegyTM
    • Fibromun
    • Darleukin
    • Dodekin
    • Dekavil
    • ABBV-022
    • Onco IX
    • OncoFAP
    • FAP-IL12
    • Tripokin
  • Press Releases & Events
  • Work with us
    • Careers
    • Partnering
  • About us
    • Profile
    • Management
    • Board
    • Scientific Advisory Board
  • Our Science
    • Strategy
    • Enabling Technologies
    • Product Classes
  • Pipeline
    • Pipeline
    • NidlegyTM
    • Fibromun
    • Darleukin
    • Dekavil
    • Dodekin
    • Onco IX
    • OncoFAP
    • FAP-IL12
    • Tripokin
  • Press Releases & Events
  • Work with us
    • Careers
    • Partnering
  • Investors
    • Investor Relations
    • Shareholding
    • IPO
    • Press Releases
    • Financial Statements
    • Financial Calendar
    • Internal Dealing
    • Buyback
    • Analyst Coverage
    • Webinars
    • IR Contacts
  • Governance
    • Board of Directors
    • Board of Statutory Auditors
    • Documents & Procedures
    • Shareholders’ Meetings
    • Codice etico e Modello 231
    • Sustainability (ESG)

Philogen S.p.A. announces its Half Year 2021 Results on Tuesday 28th September 2021

Sep 6, 2021 | 2021, Investors, Press Releases

Philogen to hold a Webinar on Wednesday 29th of September 2021 at 12:00 ET / 17:00 BST / 18:00 CEST (Please find the link to this Webinar here) Download pdf file  

Philochem, InterX and Scripps Research announce a Research Collaboration in the Field of DNA-Encoded Chemistry and Tumor Targeting

Aug 23, 2021 | 2021, Press Releases, Scientific

Philochem, a wholly owned subsidiary of Philogen S.p.A., InterX, Inc and Scripps Research announce a research collaboration to develop a best-in-class tumor targeting agent for metastatic prostate cancer. Read More

Philogen Announces First Quarter 2021 Results

May 21, 2021 | Investors, Press Releases

Philogen Announces First Quarter 2021 Results and Provides Update on Pipeline Progress

Philogen annuncia i risultati del primo trimestre 2021

May 12, 2021 | Investors, Press Releases

Philogen annuncia i risultati del primo trimestre 2021 e fornisce un aggiornamento sui progressi della pipeline

The Board of Directors approves the net financial position for the first quarter of 2021

May 12, 2021 | Investors, Press Releases

The Board of Directors approves the net financial position for the first quarter of 2021 in the amount of 104,668 thousand euro, and acknowledges the progress of the main clinical trials on Nidlegy™ and Fibromun in line with the expected timelines (Price...
« Older Entries

Recent Posts

  • Philogen to attend the European Bispecific and Multispecific Antibody congress in Amsterdam on the 22nd and 23rd of February, 2023
  • Philogen to attend the 7th Annual Next-Gen Immuno-Oncology Conference congress in London on the 9th and 10th of March, 2023
  • 23 gennaio 2023 – Aggiornamento sul programma di acquisto di azioni proprie
  • 16 gennaio 2023 – Aggiornamento sul programma di acquisto di azioni proprie
  • 09 gennaio 2023 – Aggiornamento sul programma di acquisto di azioni proprie

Recent Comments

    Privacy Policy / Cookie Policy

      Contacts

    • Follow
    • Follow

    Philogen S.p.A. ©  Piazza La Lizza, 7 | 53100 Siena (SI) – ITALY | Nr. REA: SI-98772 | P.IVA e CF 00893990523 | Cap. Soc. € 5.731.226,64 i.v. | PEC: AFC@pec.philogengroup.it